Received Jul 29, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 1 | — | — |
| MMR | MEASLES + MUMPS + RUBELLA (MMR II) | MERCK & CO. INC. | 2 | Y018703 | — |
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | 1 | Z005153 | — |
| VARCEL | VARICELLA (VARIVAX) | MERCK & CO. INC. | 1 | — | — |
Patient is not symptomatic. No additional AE; Received their first dose of MMR-II on 08/17/2023. Administration of MMR-II on 07/25/25; HCP calling to report the inadvertent administration of PROQUAD and MMR-II today (07/25/25).; This spontaneous report was received from a registered nurse (R.N.) and refers to a 2-year-old patient of unknown gender. The patient's medical history, concurrent conditions, concomitant therapies, past drug reactions and allergies were not reported. On 17-AUG-2023, the patient was vaccinated with the first dose of Varicella Virus Vaccine Live (Oka-Merck) (VARIVAX) and with the first dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II), both administered for prophylaxis (dose, formulation, route of administration, anatomical site of injection, lot number and expiration date were not reported), which were both reconstituted with sterile diluent (MERCK STERILE DILUENTE) (lot number and expiration date not provided). On 25-JUL-2025, the patient was vaccinated with the second dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) (lot number Y018703 has been verified to be valid for Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live [M-M-R II], expiration date 11-NOV-2026) (Inappropriate schedule of product administration), and with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD) dose number 1 (lot number Z005153 has been verified to be valid for Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live [PROQUAD], expiration date 25-AUG-2026); both vaccines were administered for prophylaxis (dose, vaccination scheme frequency, route of administration and anatomical site of injection were not provided) and both were reconstituted with sterile diluent (MERCK STERILE DILUENT) (lot number and expiration date were not reported). The administered vaccines were giving inadvertently on the same date (Accidental overdose). The patient was no symptomatic and no additional adverse event was reported. No other information provided This is one of two reports from the same reporter.